Advertisement

Organisation › Details
Halozyme Therapeutics Inc. (Nasdaq: HALO)
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched more than 800,000 patient lives in post-marketing use in eight commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. *
![]() |
Start | 1998-01-01 established |
Group | Halozyme (Group) | |
![]() |
Industry | biopharmaceutical |
Industry 2 | drug delivery technology (drug formulation technology) | |
![]() |
Region | San Diego, CA |
Country | United States (USA) | |
Street | 12390 El Camino Real | |
City | 92130 San Diego, CA | |
Tel | +1-858-794-8889 | |
Address record changed: 2024-11-20 | ||
Basic data | Employees | D: 101 to 500 (2024-02-12) |
Currency | USD | |
Annual sales | 829,253,000 (revenues, total, consolidated (2023) 2023-12-31) | |
Profit | 281,594,000 (2023-12-31) | |
Cash | 326,000,000 (2023-12-31) | |
* Document for »About Section«: Halozyme Therapeutics, Inc.. (11/14/24). "Press Release: Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction". San Diego, CA. | ||
Record changed: 2024-11-23 |
Advertisement

More documents for Halozyme (Group)
- [1] Halozyme Therapeutics, Inc.. (11/22/24). "Press Release: Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions". San Diego, CA....
- [2] Halozyme Therapeutics, Inc.. (11/18/24). "Press Release: Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec". San Diego, CA....
- [3] Halozyme Therapeutics, Inc.. (11/14/24). "Press Release: Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction". San Diego, CA....
- [4] Halozyme Therapeutics, Inc.. (5/24/22). "Press Release: Halozyme Completes Antares Pharma Acquisition". San Diego, CA....
- [5] Halozyme Therapeutics, Inc.. (4/13/22). "Press Release: Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader". San Diego, CA & Ewing, NJ....
- [6] Halozyme Therapeutics, Inc.. (3/24/22). "Press Release: Halozyme Therapeutics, Inc. and Chugai Pharmaceutical Enter Global Collaboration and License Agreement for Enhanze Technology". San Diego, CA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement

» top